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Background
Adoptive transfer of tumor-infiltrating lymphocytes
(TIL) can mediate complete regression of metastatic cer-
vical cancer, but the immunological landscape of the
anti-tumor T cell responses in these patients is not fully
understood. Reactivity against the human papillomavirus
(HPV)-derived antigens may contribute to the clinical
responses, but whether other immunogenic tumor anti-
gens are also targeted by these effective TIL is unknown.
Tumor-specific neo-antigens arising from somatically
mutated genes are thought to be important for the ther-
apeutic efficacy of immunotherapies in a variety of solid
tumors. Cervical cancers also harbor somatic mutations
that may be the targets of tumor-specific T cells.
Here we assessed whether mutated neo-antigens were
the targets of clinically effective TIL in a patient with
metastatic HPV16+ cervical cancer who experienced
complete tumor regression, ongoing beyond 2 years,
after TIL therapy.
Methods
Whole-exome sequencing of a metastatic tumor was
performed to identify tumor-specific non-synonymous
somatic mutations. Subsequently, minigene constructs
encoding 222 putative mutations (25-mer amino acid
sequence with the mutated amino acid centrally located)
were generated and transfected into autologous antigen
presenting cells. Finally, reactivity of TIL against the
transfected mutated minigene constructs was assessed
by IFN-g ELISPOT, and up-regulation of T cell activa-
tion markers by flow cytometry.
Results
The patient’s infused TIL were previously reported to
contain T cell reactivity against the HPV E6 and E7
antigens. Here, we found that these TIL also contained
CD8+ T cell reactivity against three mutated neo-
antigens encoded by the SETDB1, METTL17 and
ALDH1A1 genes. The mutation-reactive CD8+ T cells
showed exclusive recognition of their mutant 25-mer
peptide over the wild-type counterpart, suggesting bona
fide mutation-driven T cell reactivities. Furthermore,
mutated neo-antigen T cell reactivities comprised ~24%
of the infused TIL as assessed by CD137 up-regulation
assay, and were mono- to oligoclonal as suggested by
T cell receptor Vb chain analysis of mutation-reactive
bulk-isolated populations. Finally, no T cell reactivity
against mutated antigens was detectable in peripheral
blood pre-treatment, while mutation-reactive CD8+
T cells were present in peripheral blood at one month
post-treatment. Analysis of mutation-derived neo-antigen
T cell reactivities in additional HPV+ cancer patients
treated with TIL therapy is currently ongoing.
Conclusions
Our data reveal that mutated neo-antigens, in addition
to previously reported HPV antigens, were the targets of
clinically effective TIL in a patient with metastatic HPV
+ cervical cancer who experienced complete tumor
regression. This finding has important implications for
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future study and understanding of anti-tumor T cell
responses in HPV+ cancers.
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